Krystal Biotech Corp. (KRYS) - מקדם חוב לטווח ארוך להון

Rapid sales expansion driven by in-house production creates powerful operating leverage, with the indicator standing at 0.01. The pricing evolution of Krystal Biotech, Inc. (KRYS) demonstrates the influence of its gene delivery ecosystem, which is setting new medical standards for the therapy of skin pathologies. At the core of the business lies an innovative biotech platform that ensures a monopoly position in the treatment of rare dermatological diseases for clinics and private patients.

This indicator determines the share of long-term liabilities within the total capital structure, identifying the balance sheet's resilience to external shocks. By analyzing the long-term debt-to-equity ratio, an investor can see the impact of asset revaluation on the credit load, which for Krystal Biotech, Inc. (KRYS) is confirmed by investments in its own manufacturing plants alongside the moderate use of external vendors for clinical trials.